LSD1: an emerging face in altering the tumor microenvironment and enhancing immune checkpoint therapy

Table 1 LSD1 in combination with immune checkpoint inhibition

IC protein	Treatment type	Treatment effects	Type of cancer	References
PD-1	Combination of LSD1 and PD-1 inhibition	Increase the longevity of tumor-killing capacity of CD8 T cells	Colon cancer	[43]
	LSD1 inhibition	Increase PD-1 mRNA and protein	Infiltrated CD8 T cell in a mouse melanoma model	[38]
	Combination of LSD1 and PD-1 inhibition	1) Induces cytotoxic CD8 T cell infiltration 2) Enhance in vivo breast tumor immunogenicity 3) Inhibit metastasis	Breast cancer	[87]
	Combination of LSD1, TGFβ and PD-1 blockade	Increase infiltration and cytotoxicity of CD8 T cells	Melanoma	[25]
PD-L1	LSD1 inhibition	1) Increase effectiveness of CD8 T cell-mediated cytotoxicity 2) Decrease PD-L1 expression	Hepatocellular carcinoma	[97]
	LSD1 inhibition	Decrease exosomal PD-L1 and restore CD8 T cell response	Gastric cancer	[41]
	LSD1 inhibitor combined with PD-L1 antibody	Decrease PD-L1 expression	Cervical cancer	[37]
	LSD1 deletion	Increase PD-L1 expression	Head and neck squamous cell carcinoma	[98]
CTLA4	Combination of LSD1, PD-L1 and CTLA4 inhibition in SWI/SNF mutatated cells	Increase PBMC penetration	Ovarian clear cell carcinomas and small cell carcinoma of the ovary hypercalcemic type	[99]

ISSN: 1423-0127